Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
INF904 is an orally administered low molecular weight C5aR inhibitor which is under phase 1 clinical development for the treatment of inflammatory diseases.
Lead Product(s): INF904
Therapeutic Area: Immunology Product Name: INF904
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which demonstrates high selectivity towards its target in human blood, investigated for the treatment of Pyoderma Gangrenosum.
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: Gohibic
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
INF904 is an orally administered small molecule inhibitor of C5a-induced signaling via the receptor C5aR, which is investigated for the treatment of inflammatory diseases.
Lead Product(s): INF904
Therapeutic Area: Immunology Product Name: INF904
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which demonstrates high selectivity towards its target in human blood, used for the treatment of Critically Ill COVID-19 Patients.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody that has been granted an approval for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
Under the terms of the agreement, WuXi Biologics will provide cGMP manufacturing of Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody for the treatment of COVID-19.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: WuXi Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 16, 2023
Details:
The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab), a chimeric monoclonal IgG4 antibody that specifically binds with high affinity to the soluble form of human C5a.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 18, 2023
Details:
The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab),a chimeric monoclonal IgG4 antibody that specifically binds with high affinity to the soluble form of human C5a.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 14, 2023
Details:
The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab), an anti-C5a monoclonal antibody, in patients with severe COVID-19.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 11, 2023
Details:
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody that has been granted an EUA for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023